Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455231 | 1.00 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL15308134 | 0.88 | DHFR (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL30424499 | 0.84 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL15303335 | 0.84 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL3632188 | 0.84 | DHFR (0.46) | SLC5A2SLC5A1MEN1KMT2A | |
| SCHEMBL11313959 | 0.84 | SLC5A2 (0.55) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL2871442 | 0.83 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL15308132 | 0.83 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL2707322 | 0.83 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL15308138 | 0.82 | SLC5A2 (0.47) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250178996-A1 | SGLT2 INHIBITOR INTERMEDIATE V-1 AND USE THEREOF | WANBANG BIOPHARMACEUTICALS (CN) | 2025-06-05 | — | — | US | claimed |
| CN-116535299-A | SGLT2 inhibitor intermediate V-1 and application thereof | 江苏万邦生化医药集团有限责任公司 | 2023-08-04 | — | — | CN | claimed |
| WO-2023142238-A1 | SGLT2 INHIBITOR INTERMEDIATE V-1 AND USE THEREOF | 江苏万邦生化医药集团有限责任公司 | 2023-08-03 | — | — | WO | claimed |
| CN-114570303-A | Microchannel reactor and method for preparing dapagliflozin intermediate based on reactor | 南京市计量监督检测院 | 2022-06-03 | — | — | CN | claimed |
| CN-111057032-B | Preparation method of dapagliflozin | 东南大学 | 2022-03-11 | — | — | CN | claimed |
| CN-109232199-B | Synthesis method of 1-chloro-2- (4-ethoxybenzyl) -4-iodobenzene | 南京红杉生物科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-111057032-A | Preparation method of dapagliflozin | 东南大学 | 2020-04-24 | — | — | CN | claimed |
| US-20250178996-A1 | SGLT2 INHIBITOR INTERMEDIATE V-1 AND USE THEREOF | WANBANG BIOPHARMACEUTICALS (CN) | 2025-06-05 | — | — | US | disclosed |
| US-20250042930-A1 | METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG | SICHUAN UNIVERSITY (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-118063294-A | Efficient preparation method of dapagliflozin intermediate | 山东新时代药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118063294-A | Efficient preparation method of dapagliflozin intermediate | 山东新时代药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117756611-A | Preparation method of dapagliflozin intermediate | 山东新时代药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756611-A | Preparation method of dapagliflozin intermediate | 山东新时代药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2010009197-A1 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016422-A1 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-01-21 | — | — | US | disclosed |
| US-20090030198-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-01-29 | — | — | US | disclosed |
| US-20090030198-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-01-29 | — | — | US | disclosed |
| US-20090030198-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-01-29 | — | — | US | disclosed |
| WO-2009014970-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009014970-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030198-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | SLC2A2, SLC2A1, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885ADRA2A 1593/4885 |
| US-20100016422-A1 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE | TPMT, PYGL, PNPO | SLC5A2 233/4885SLC5A1 354/4885ADRA2A 2928/4885 |
| US-20250178996-A1 | SGLT2 INHIBITOR INTERMEDIATE V-1 AND USE THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 792/4885 |
| US-20250042930-A1 | METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG | UGGT1, GCG, SLC5A2 | SLC5A2 3/4885SLC5A1 6/4885ADRA2A 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.